BLPH Archives - BioTuesdays

Developments

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

The last patient has completed blinded treatment in Bellerophon Therapeutics’ (NASDAQ:BLPH) Phase 3 REBUILD study of INOpulse, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic...

May 11, 2023

Developments

Bellerophon enrolls first patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) enrolled the first patient in its Phase 3 REBUILD study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of fibrotic interstitial lung disease (fILD). The study...

December 1, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Markets

Brookline starts Bellerophon Therapeutics at buy; PT $35

Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...

April 14, 2020

Developments

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

Bellerophon Therapeutics (NASDAQ:BLPH) submitted an IND to the FDA to study INOpulse, a pulsed nitric oxide (NO) system, for the treatment of patients with COVID-19. The IND follows the FDA’s allowance of treatment with...

April 9, 2020

Developments

Bellerophon reports positive topline data from Phase 2 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) reported positive top-line data from PHPF-002, a dose escalation, hemodynamics study of INOpulse for the treatment of pulmonary hypertension associated with pulmonary fibrosis. The...

February 18, 2020

Developments

Bellerophon gets FDA orphan drug designation for IPF therapy

Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the...

September 16, 2019

Markets

Maxim starts Bellerophon Therapeutics at buy; PT $3

Maxim Group initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $3 price target. The stock closed at 67 cents on Jan. 23. Bellerophon’s lead product is the INOpulse delivery system of...

January 24, 2019

Markets

Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13. Bellerophon is developing and optimizing...

April 17, 2017

Markets

HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20. Bellerophon develops products for the treatment of...

January 23, 2017

Tag - BLPH

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

Bellerophon enrolls first patient in Phase 3 INOpulse study

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Brookline starts Bellerophon Therapeutics at buy; PT $35

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

Bellerophon reports positive topline data from Phase 2 INOpulse study

Bellerophon gets FDA orphan drug designation for IPF therapy

Maxim starts Bellerophon Therapeutics at buy; PT $3

Ladenburg starts Bellerophon at buy

HCW starts Bellerophon Therapeutics at buy

General

More